Organogenesis Q2 Adj EPS $0.46 Beats $0.02 Estimate, Sales $117.32M Beat $115.10M Estimate
Portfolio Pulse from Benzinga Newsdesk
Organogenesis Holdings (NASDAQ:ORGO) reported Q2 adjusted earnings of $0.46 per share, beating the analyst consensus estimate of $0.02 by 2200 percent. This is a 411.11 percent increase from the same period last year. The company also reported quarterly sales of $117.32 million, beating the analyst consensus estimate of $115.10 million by 1.93 percent, although this is a 3.36 percent decrease from the same period last year.
August 09, 2023 | 8:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Organogenesis Holdings reported a significant increase in Q2 earnings and beat sales estimates, which could positively impact the stock.
Organogenesis Holdings reported a significant increase in Q2 earnings, beating analyst estimates by a large margin. This positive financial performance could increase investor confidence and drive the stock price up. However, the decrease in sales compared to the same period last year might temper this positive impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100